Abstract
To analyze the distribution of apolipoprotein E (Apo E) phenotypes between patients with Creutzfeldt-Jakob disease (CJD) and control subjects. University hospital, base of the German National CJD Surveillance Study. Prospective case-control study. Sixty-two patients with definite or probable CJD, 90 patients with initial suspected CJO, and 51 controls matched for age, sex, and place of residence. Phenotyping of Apo E in serum by isoelectric focusing, assessment of the gels by 3 independent investigators, measurement of of Apo E in cerebrospinal fluid using an enzyme-linked immunosorbent assay, and calculation of Kaplan-Meier cumulative survival plots. The most frequent phenotype was E 3-3 with 56% in patients and 59% in controls, followed by E 3-4 with a frequency of 29% vs 25%, respectively. The phenotype E 3-2 was much rarer (13% vs 16%, respectively). Patients with definite CJD had a mean (SD) Apo E concentration of 3.4 (2.0) mg/L; patients with probable CJD, 3.1 (1.6) mg/L; patients with possible CJD, 3.8 (2.2) mg/L; and subjects with other diseases, 3.0 (1.7) mg/L. Mean (SD) disease duration for patients with E 3-2 was 11.8 (9.8) months; for patients with E 3-3, 12.0 (9.02) months; and for patients with E 3-4, 14.2 (12.3) ...Continue Reading
Citations
Dec 18, 2013·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Yunfei WeiChao Qin
Dec 25, 2007·Journal of Molecular Neuroscience : MN·Anna KrasnianskiInga Zerr
Oct 31, 2001·Neuroscience Letters·B Van EverbroeckP Cras
May 7, 2009·Journal of Neurology·Inês Esteves BaldeirasCatarina Resende Oliveira
Jan 26, 2013·Epidemiologic Reviews·Francis Mawanda, Robert Wallace
Sep 2, 2008·Brain : a Journal of Neurology·T E F WebbS Mead
Jan 5, 2016·Neurobiology of Aging·Seon-Mi ParkByung-Hoon Jeong
Sep 8, 2007·Neurobiology of Aging·Anna KrasnianskiInga Zerr
Oct 10, 2006·Bioscience Reports·Fabio CoppedèLuigi Murri
Jul 30, 2011·PloS One·Olga CaleroMiguel Calero
Feb 19, 1999·Biological Psychiatry·K OharaK Ohara
Jan 15, 2003·Journal of Clinical Laboratory Analysis·P D MehtaP S Aisen
Feb 26, 2011·Lancet Neurology·Philip B VergheseDavid M Holtzman